FREE Daily Stock Alerts From Stock-PR.com
Power3 Medical Products, Inc. (OTC:PWRM)
BC-SeraPro™ is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient's serum sample is compared to the Power3 Medical Products' patient database. Statistical analysis by linear discriminant function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis of the patient sample. Probability score is ranged from 0.0 to 1.0. Results of the BC-SeraPro™ test should not be considered a standalone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.
Breast cancer is one of the common malignancies afflicting women. In several parts it is the most common malignancy. It is currently estimated that one in fourteen of all female children born will develop breast cancer in their lifetime. Despite extensive investigation into the cause of breast cancer there is still no known cause. However, a combination of environmental factors and genetic mutations are thought to be responsible for this cancer. In familial breast cancers, a molecular change in the genes BRCA1 and BRCA2 play a major role in the onset of the disease.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 Medical applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroProÂ®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
For more information, please visit http://www.power3medical.com.
Medicines Co. (Nasdaq:MDCO) will present at the Jefferies Global Healthcare Conference on Tuesday, June 7th, in New York beginning at 8:00am Eastern Time. Glenn Sblendorio, Executive Vice President and Chief Financial Officer, will provide a company overview. The session will be webcast with a link available at The Medicines Company's website http://www.themedicinescompany.com.
The Medicines Company operates as a global pharmaceutical company with a focus on advancing the treatment of critical care patients. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.
Amarin Corporation plc (Nasdaq:AMRN) clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced the expansion of its capability to supply AMR101 through the addition of two active pharmaceutical ingredient (NYSEMKT:API) suppliers and two encapsulators. Equateq Limited (Equateq) and Chemport Inc. (Chemport) have agreed to provide Amarin with API for AMR101. Catalent Pharma Solutions LLC (Catalent) and Banner Pharmacaps Europe B.V. (Banner) have agreed to terms with Amarin to provide soft-gel encapsulation services for AMR101. These agreements expand Amarin's entire supply chain and provide the Company with significantly greater global capacity and diversification in preparation for the commercial launch of AMR101.
Amarin Corporation Plc, a clinical-stage biopharmaceutical company, focuses on developing treatments for cardiovascular diseases. The company, formerly known as Ethical Holdings plc, was founded in 1989 and is based in Dublin, Ireland.
United Fire & Casualty Company (Nasdaq:UFCS) announced that it has entered into an agreement and plan of reorganization with United Fire Group, Inc. ("United Fire Group"), a newly-formed wholly owned subsidiary of United Fire, and UFC MergeCo, Inc. ("MergeCo"), a newly-formed wholly owned subsidiary of United Fire Group. A registration statement on Form S-4 has been filed with the U.S. Securities and Exchange Commission for United Fire's proposed reorganization.
United Fire & Casualty Company, together with its subsidiaries, engages in writing property, casualty, and life insurance; and selling annuities in the United States. United Fire & Casualty Company was founded in 1946 and is headquartered in Cedar Rapids, Iowa.
Majestic Gold Corp. (MJS.V)
A recently announced agreement will increase Majestic's effective ownership from 54 to 94 % and has allowed the property to commence production at an initial rate of 1,400 tpd. With a contract that fixes operating costs and allows use of land and equipment, Majestic anticipates to have a positive cash flow, within a matter of months.
Majestic Gold Corp. is pleased to provide a progress update on the new mill construction for the company's flagship Song Jiagou project.
The mill is in the commissioning stage and has begun running ore through the mill in order to access the efficiency of the mill. Majestic expects to run at an initial throughput rate of 3,000 tons per day and progressively move upwards towards full capacity of 6,000 tons per day once the mill is running at optimal efficiency.
Ore that has been stockpiled at the new mill in order to streamline the commissioning process is currently being processed as part of the commissioning stage. In addition, Majestic is pleased to announce that the tailings dam is fully completed and all tailings lines and water return systems are in place and now in use.
They are excited by the prospect of getting the new mill on line and being in a position to significantly increase production levels. This represents a significant milestone in their transition from exploration to production.
Majestic Gold Corp. is a Vancouver-based; TSX Venture Exchange and Frankfurt Exchange listed gold exploration and Development Company with a very advanced gold deposit in Shandong province of China. At present, Majestic Gold Corp. is aggressively pursuing a pre-feasibility study.
Gold's other main role in electronics is in semi-conductor devices, where fine gold wire or strip is used to connect parts such as transistors and integrated circuits, and in printed circuit boards to link components. Again, the need for reliable connections makes gold indispensable. This bonding wire is one of the most specialized uses of gold; it is highly refined to 999.99 purity and the wire has a typical diameter of one-hundredth of a millimeter.
For more information, please visit their website: http://www.majesticgold.net
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).
Sign Up For Free Stock Alerts At http://stock-pr.com/signup